Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI

Patent ExpiryFILSPARIPositive

AI Analysis

Summary

Travere Therapeutics received a US patent allowance for FILSPARI, its kidney disease drug. This intellectual property protection strengthens the company's position for the candidate.

Outcome Details

US patent allowance received

Importance:5/10

Sentiment:

0.60

patentintellectual propertyFILSPARIkidney diseaseregulatory

Related Companies

$TVTX

Read the original article

Published by yahoo_finance on September 23, 2026 11:49 AM

Read Original